Global Neurodegenerative Drugs

Neurodegenerative Drugs Comprehensive Study by Route of Administration (Oral, Injection, Transdermal, Others), Distribution Channel (Retail Pharmacy, Hospital Pharmacy, Online Pharmacy), Indication (Alzheimer Disease, Parkinson Disease, Multiple Sclerosis, Others), Drug Class (Glutamate Regulators, Decarboxylase Inhibitors, Dopamine Agonist, Cholinesterase Inhibitors, Others) Players and Region - Global Market Outlook to 2030

Neurodegenerative Drugs Market by XX Submarkets | Forecast Years 2024-2030  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
About Neurodegenerative Drugs
Neurodegenerative drugs are medications used to treat or manage the symptoms of neurodegenerative diseases. These are diseases that cause progressive damage and loss of nerve cells in the brain and spinal cord. There are some different types of neurodegenerative drugs such as Acetylcholinesterase inhibitors, Dopamine agonists, Antiparkinsonian medications, and Glutamate antagonists. The Neurodegenerative Drugs market is poised for significant growth due to the confluence of rising disease burden, unmet medical needs, and advancements in research and development.

AttributesDetails
Study Period2018-2030
Base Year2023
UnitValue (USD Million)


The market is seeing moderate market players, by seeing huge growth in this market the key leading vendors are highly focusing on production technologies, efficiency enhancement, and product life. This market has various growth opportunities that leading players capture via tracking the ongoing process enhancement and huge investment in market growth strategies. Analyst at AMA Research estimates that United States Players will contribute the maximum growth to Global Neurodegenerative Drugs market throughout the forecasted period. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.

AbbVie Inc. (United States), GSK plc (United Kingdom), Johnson & Johnson Services, Inc. (United States), Biogen (United States), Merck & Co., Inc. (United States), Novartis AG (Switzerland), Bristol-Myers Squibb (United States), Lilly (United States), Eisai Co., Ltd. (Japan) and F. Hoffmann-La Roche Ltd. (Switzerland) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research coverage are H. Lundbeck A/S (United Kingdom), Acadia Pharmaceuticals Inc. (United States), Supernus Pharmaceuticals, Inc. (United States), Alkermes (Ireland) and Amgen Inc. (United States).

Segmentation Overview
AMA Research has segmented the market of Global Neurodegenerative Drugs market by and Region.



On the basis of geography, the market of Neurodegenerative Drugs has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by Route of Administration, the sub-segment i.e. Oral will boost the Neurodegenerative Drugs market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Distribution Channel, the sub-segment i.e. Retail Pharmacy will boost the Neurodegenerative Drugs market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Indication , the sub-segment i.e. Alzheimer Disease will boost the Neurodegenerative Drugs market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Drug Class, the sub-segment i.e. Glutamate Regulators will boost the Neurodegenerative Drugs market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Influencing Trend:
Increasing Adoption of Cholinesterase Inhibitors

Market Growth Drivers:
Increase in Prevalence of Neurodegenerative Diseases and Growing Awareness of Neurodegenerative Diseases

Challenges:
Lack of Skilled Professionals and Infrastructure in Developing Economies

Restraints:
High Cost of Drug Development

Opportunities:
Untapped Potential in Emerging Markets and Increased Government and Private Funding for Research

Market Leaders and their expansionary development strategies
In July 2021, GlaxoSmithKline (GSK) and Alector announced a global collaboration in immuno-neurology for two clinical-stage first-in-class monoclonal antibodies AL001 and AL101, for a range of neurodegenerative diseases, including frontotemporal dementia, amyotrophic lateral sclerosis, Parkinson’s disease, and Alzheimer’s disease.
In June 2021, Biogen and Eisai launched multiple initiatives to help patients with Alzheimer’s disease access ADUHELM. ADUHELM reduces amyloid beta plaques, a protein buildup in the brain associated with Alzheimer's disease.


Key Target Audience
Government Bodies, Research Center, Research & Consultancy Firms, Regulatory Authorities and Others

About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have a better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with the purpose to understand the companies positioning regarding the market value, volume, and their market share for regional as well as global.

Further to bring relevance specific to any niche market we set and apply a number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders, etc., and work towards appointment generation.

The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, the analyst team keeps preparing a set of questionnaires, and after getting the appointee list; the target audience is then tapped and segregated with various mediums and channels that are feasible for making connections that including email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey, etc.

Report Objectives / Segmentation Covered

By Route of Administration
  • Oral
  • Injection
  • Transdermal
  • Others

By Distribution Channel
  • Retail Pharmacy
  • Hospital Pharmacy
  • Online Pharmacy

By Indication
  • Alzheimer Disease
  • Parkinson Disease
  • Multiple Sclerosis
  • Others

By Drug Class
  • Glutamate Regulators
  • Decarboxylase Inhibitors
  • Dopamine Agonist
  • Cholinesterase Inhibitors
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increase in Prevalence of Neurodegenerative Diseases
      • 3.2.2. Growing Awareness of Neurodegenerative Diseases
    • 3.3. Market Challenges
      • 3.3.1. Lack of Skilled Professionals and Infrastructure in Developing Economies
    • 3.4. Market Trends
      • 3.4.1. Increasing Adoption of Cholinesterase Inhibitors
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Neurodegenerative Drugs, by Route of Administration, Distribution Channel, Indication , Drug Class and Region (value, volume and price ) (2018-2023)
    • 5.1. Introduction
    • 5.2. Global Neurodegenerative Drugs (Value)
      • 5.2.1. Global Neurodegenerative Drugs by: Route of Administration (Value)
        • 5.2.1.1. Oral
        • 5.2.1.2. Injection
        • 5.2.1.3. Transdermal
        • 5.2.1.4. Others
      • 5.2.2. Global Neurodegenerative Drugs by: Distribution Channel (Value)
        • 5.2.2.1. Retail Pharmacy
        • 5.2.2.2. Hospital Pharmacy
        • 5.2.2.3. Online Pharmacy
      • 5.2.3. Global Neurodegenerative Drugs by: Drug Class (Value)
        • 5.2.3.1. Glutamate Regulators
        • 5.2.3.2. Decarboxylase Inhibitors
        • 5.2.3.3. Dopamine Agonist
        • 5.2.3.4. Cholinesterase Inhibitors
        • 5.2.3.5. Others
      • 5.2.4. Global Neurodegenerative Drugs Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
    • 5.3. Global Neurodegenerative Drugs (Volume)
      • 5.3.1. Global Neurodegenerative Drugs by: Route of Administration (Volume)
        • 5.3.1.1. Oral
        • 5.3.1.2. Injection
        • 5.3.1.3. Transdermal
        • 5.3.1.4. Others
      • 5.3.2. Global Neurodegenerative Drugs by: Distribution Channel (Volume)
        • 5.3.2.1. Retail Pharmacy
        • 5.3.2.2. Hospital Pharmacy
        • 5.3.2.3. Online Pharmacy
      • 5.3.3. Global Neurodegenerative Drugs by: Drug Class (Volume)
        • 5.3.3.1. Glutamate Regulators
        • 5.3.3.2. Decarboxylase Inhibitors
        • 5.3.3.3. Dopamine Agonist
        • 5.3.3.4. Cholinesterase Inhibitors
        • 5.3.3.5. Others
      • 5.3.4. Global Neurodegenerative Drugs Region
        • 5.3.4.1. South America
          • 5.3.4.1.1. Brazil
          • 5.3.4.1.2. Argentina
          • 5.3.4.1.3. Rest of South America
        • 5.3.4.2. Asia Pacific
          • 5.3.4.2.1. China
          • 5.3.4.2.2. Japan
          • 5.3.4.2.3. India
          • 5.3.4.2.4. South Korea
          • 5.3.4.2.5. Taiwan
          • 5.3.4.2.6. Australia
          • 5.3.4.2.7. Rest of Asia-Pacific
        • 5.3.4.3. Europe
          • 5.3.4.3.1. Germany
          • 5.3.4.3.2. France
          • 5.3.4.3.3. Italy
          • 5.3.4.3.4. United Kingdom
          • 5.3.4.3.5. Netherlands
          • 5.3.4.3.6. Rest of Europe
        • 5.3.4.4. MEA
          • 5.3.4.4.1. Middle East
          • 5.3.4.4.2. Africa
        • 5.3.4.5. North America
          • 5.3.4.5.1. United States
          • 5.3.4.5.2. Canada
          • 5.3.4.5.3. Mexico
    • 5.4. Global Neurodegenerative Drugs (Price)
  • 6. Neurodegenerative Drugs: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2023)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. AbbVie Inc. (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. GSK plc (United Kingdom)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Johnson & Johnson Services, Inc. (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Biogen (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Merck & Co., Inc. (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Novartis AG (Switzerland)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Bristol-Myers Squibb (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Lilly (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Eisai Co., Ltd. (Japan)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. F. Hoffmann-La Roche Ltd. (Switzerland)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Neurodegenerative Drugs Sale, by Route of Administration, Distribution Channel, Indication , Drug Class and Region (value, volume and price ) (2025-2030)
    • 7.1. Introduction
    • 7.2. Global Neurodegenerative Drugs (Value)
      • 7.2.1. Global Neurodegenerative Drugs by: Route of Administration (Value)
        • 7.2.1.1. Oral
        • 7.2.1.2. Injection
        • 7.2.1.3. Transdermal
        • 7.2.1.4. Others
      • 7.2.2. Global Neurodegenerative Drugs by: Distribution Channel (Value)
        • 7.2.2.1. Retail Pharmacy
        • 7.2.2.2. Hospital Pharmacy
        • 7.2.2.3. Online Pharmacy
      • 7.2.3. Global Neurodegenerative Drugs by: Drug Class (Value)
        • 7.2.3.1. Glutamate Regulators
        • 7.2.3.2. Decarboxylase Inhibitors
        • 7.2.3.3. Dopamine Agonist
        • 7.2.3.4. Cholinesterase Inhibitors
        • 7.2.3.5. Others
      • 7.2.4. Global Neurodegenerative Drugs Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
    • 7.3. Global Neurodegenerative Drugs (Volume)
      • 7.3.1. Global Neurodegenerative Drugs by: Route of Administration (Volume)
        • 7.3.1.1. Oral
        • 7.3.1.2. Injection
        • 7.3.1.3. Transdermal
        • 7.3.1.4. Others
      • 7.3.2. Global Neurodegenerative Drugs by: Distribution Channel (Volume)
        • 7.3.2.1. Retail Pharmacy
        • 7.3.2.2. Hospital Pharmacy
        • 7.3.2.3. Online Pharmacy
      • 7.3.3. Global Neurodegenerative Drugs by: Drug Class (Volume)
        • 7.3.3.1. Glutamate Regulators
        • 7.3.3.2. Decarboxylase Inhibitors
        • 7.3.3.3. Dopamine Agonist
        • 7.3.3.4. Cholinesterase Inhibitors
        • 7.3.3.5. Others
      • 7.3.4. Global Neurodegenerative Drugs Region
        • 7.3.4.1. South America
          • 7.3.4.1.1. Brazil
          • 7.3.4.1.2. Argentina
          • 7.3.4.1.3. Rest of South America
        • 7.3.4.2. Asia Pacific
          • 7.3.4.2.1. China
          • 7.3.4.2.2. Japan
          • 7.3.4.2.3. India
          • 7.3.4.2.4. South Korea
          • 7.3.4.2.5. Taiwan
          • 7.3.4.2.6. Australia
          • 7.3.4.2.7. Rest of Asia-Pacific
        • 7.3.4.3. Europe
          • 7.3.4.3.1. Germany
          • 7.3.4.3.2. France
          • 7.3.4.3.3. Italy
          • 7.3.4.3.4. United Kingdom
          • 7.3.4.3.5. Netherlands
          • 7.3.4.3.6. Rest of Europe
        • 7.3.4.4. MEA
          • 7.3.4.4.1. Middle East
          • 7.3.4.4.2. Africa
        • 7.3.4.5. North America
          • 7.3.4.5.1. United States
          • 7.3.4.5.2. Canada
          • 7.3.4.5.3. Mexico
    • 7.4. Global Neurodegenerative Drugs (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Neurodegenerative Drugs: by Route of Administration(USD Million)
  • Table 2. Neurodegenerative Drugs Oral , by Region USD Million (2018-2023)
  • Table 3. Neurodegenerative Drugs Injection , by Region USD Million (2018-2023)
  • Table 4. Neurodegenerative Drugs Transdermal , by Region USD Million (2018-2023)
  • Table 5. Neurodegenerative Drugs Others , by Region USD Million (2018-2023)
  • Table 6. Neurodegenerative Drugs: by Distribution Channel(USD Million)
  • Table 7. Neurodegenerative Drugs Retail Pharmacy , by Region USD Million (2018-2023)
  • Table 8. Neurodegenerative Drugs Hospital Pharmacy , by Region USD Million (2018-2023)
  • Table 9. Neurodegenerative Drugs Online Pharmacy , by Region USD Million (2018-2023)
  • Table 10. Neurodegenerative Drugs: by Drug Class(USD Million)
  • Table 11. Neurodegenerative Drugs Glutamate Regulators , by Region USD Million (2018-2023)
  • Table 12. Neurodegenerative Drugs Decarboxylase Inhibitors , by Region USD Million (2018-2023)
  • Table 13. Neurodegenerative Drugs Dopamine Agonist , by Region USD Million (2018-2023)
  • Table 14. Neurodegenerative Drugs Cholinesterase Inhibitors , by Region USD Million (2018-2023)
  • Table 15. Neurodegenerative Drugs Others , by Region USD Million (2018-2023)
  • Table 16. South America Neurodegenerative Drugs, by Country USD Million (2018-2023)
  • Table 17. South America Neurodegenerative Drugs, by Route of Administration USD Million (2018-2023)
  • Table 18. South America Neurodegenerative Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 19. South America Neurodegenerative Drugs, by Indication USD Million (2018-2023)
  • Table 20. South America Neurodegenerative Drugs, by Drug Class USD Million (2018-2023)
  • Table 21. Brazil Neurodegenerative Drugs, by Route of Administration USD Million (2018-2023)
  • Table 22. Brazil Neurodegenerative Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 23. Brazil Neurodegenerative Drugs, by Indication USD Million (2018-2023)
  • Table 24. Brazil Neurodegenerative Drugs, by Drug Class USD Million (2018-2023)
  • Table 25. Argentina Neurodegenerative Drugs, by Route of Administration USD Million (2018-2023)
  • Table 26. Argentina Neurodegenerative Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 27. Argentina Neurodegenerative Drugs, by Indication USD Million (2018-2023)
  • Table 28. Argentina Neurodegenerative Drugs, by Drug Class USD Million (2018-2023)
  • Table 29. Rest of South America Neurodegenerative Drugs, by Route of Administration USD Million (2018-2023)
  • Table 30. Rest of South America Neurodegenerative Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 31. Rest of South America Neurodegenerative Drugs, by Indication USD Million (2018-2023)
  • Table 32. Rest of South America Neurodegenerative Drugs, by Drug Class USD Million (2018-2023)
  • Table 33. Asia Pacific Neurodegenerative Drugs, by Country USD Million (2018-2023)
  • Table 34. Asia Pacific Neurodegenerative Drugs, by Route of Administration USD Million (2018-2023)
  • Table 35. Asia Pacific Neurodegenerative Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 36. Asia Pacific Neurodegenerative Drugs, by Indication USD Million (2018-2023)
  • Table 37. Asia Pacific Neurodegenerative Drugs, by Drug Class USD Million (2018-2023)
  • Table 38. China Neurodegenerative Drugs, by Route of Administration USD Million (2018-2023)
  • Table 39. China Neurodegenerative Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 40. China Neurodegenerative Drugs, by Indication USD Million (2018-2023)
  • Table 41. China Neurodegenerative Drugs, by Drug Class USD Million (2018-2023)
  • Table 42. Japan Neurodegenerative Drugs, by Route of Administration USD Million (2018-2023)
  • Table 43. Japan Neurodegenerative Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 44. Japan Neurodegenerative Drugs, by Indication USD Million (2018-2023)
  • Table 45. Japan Neurodegenerative Drugs, by Drug Class USD Million (2018-2023)
  • Table 46. India Neurodegenerative Drugs, by Route of Administration USD Million (2018-2023)
  • Table 47. India Neurodegenerative Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 48. India Neurodegenerative Drugs, by Indication USD Million (2018-2023)
  • Table 49. India Neurodegenerative Drugs, by Drug Class USD Million (2018-2023)
  • Table 50. South Korea Neurodegenerative Drugs, by Route of Administration USD Million (2018-2023)
  • Table 51. South Korea Neurodegenerative Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 52. South Korea Neurodegenerative Drugs, by Indication USD Million (2018-2023)
  • Table 53. South Korea Neurodegenerative Drugs, by Drug Class USD Million (2018-2023)
  • Table 54. Taiwan Neurodegenerative Drugs, by Route of Administration USD Million (2018-2023)
  • Table 55. Taiwan Neurodegenerative Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 56. Taiwan Neurodegenerative Drugs, by Indication USD Million (2018-2023)
  • Table 57. Taiwan Neurodegenerative Drugs, by Drug Class USD Million (2018-2023)
  • Table 58. Australia Neurodegenerative Drugs, by Route of Administration USD Million (2018-2023)
  • Table 59. Australia Neurodegenerative Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 60. Australia Neurodegenerative Drugs, by Indication USD Million (2018-2023)
  • Table 61. Australia Neurodegenerative Drugs, by Drug Class USD Million (2018-2023)
  • Table 62. Rest of Asia-Pacific Neurodegenerative Drugs, by Route of Administration USD Million (2018-2023)
  • Table 63. Rest of Asia-Pacific Neurodegenerative Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 64. Rest of Asia-Pacific Neurodegenerative Drugs, by Indication USD Million (2018-2023)
  • Table 65. Rest of Asia-Pacific Neurodegenerative Drugs, by Drug Class USD Million (2018-2023)
  • Table 66. Europe Neurodegenerative Drugs, by Country USD Million (2018-2023)
  • Table 67. Europe Neurodegenerative Drugs, by Route of Administration USD Million (2018-2023)
  • Table 68. Europe Neurodegenerative Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 69. Europe Neurodegenerative Drugs, by Indication USD Million (2018-2023)
  • Table 70. Europe Neurodegenerative Drugs, by Drug Class USD Million (2018-2023)
  • Table 71. Germany Neurodegenerative Drugs, by Route of Administration USD Million (2018-2023)
  • Table 72. Germany Neurodegenerative Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 73. Germany Neurodegenerative Drugs, by Indication USD Million (2018-2023)
  • Table 74. Germany Neurodegenerative Drugs, by Drug Class USD Million (2018-2023)
  • Table 75. France Neurodegenerative Drugs, by Route of Administration USD Million (2018-2023)
  • Table 76. France Neurodegenerative Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 77. France Neurodegenerative Drugs, by Indication USD Million (2018-2023)
  • Table 78. France Neurodegenerative Drugs, by Drug Class USD Million (2018-2023)
  • Table 79. Italy Neurodegenerative Drugs, by Route of Administration USD Million (2018-2023)
  • Table 80. Italy Neurodegenerative Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 81. Italy Neurodegenerative Drugs, by Indication USD Million (2018-2023)
  • Table 82. Italy Neurodegenerative Drugs, by Drug Class USD Million (2018-2023)
  • Table 83. United Kingdom Neurodegenerative Drugs, by Route of Administration USD Million (2018-2023)
  • Table 84. United Kingdom Neurodegenerative Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 85. United Kingdom Neurodegenerative Drugs, by Indication USD Million (2018-2023)
  • Table 86. United Kingdom Neurodegenerative Drugs, by Drug Class USD Million (2018-2023)
  • Table 87. Netherlands Neurodegenerative Drugs, by Route of Administration USD Million (2018-2023)
  • Table 88. Netherlands Neurodegenerative Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 89. Netherlands Neurodegenerative Drugs, by Indication USD Million (2018-2023)
  • Table 90. Netherlands Neurodegenerative Drugs, by Drug Class USD Million (2018-2023)
  • Table 91. Rest of Europe Neurodegenerative Drugs, by Route of Administration USD Million (2018-2023)
  • Table 92. Rest of Europe Neurodegenerative Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 93. Rest of Europe Neurodegenerative Drugs, by Indication USD Million (2018-2023)
  • Table 94. Rest of Europe Neurodegenerative Drugs, by Drug Class USD Million (2018-2023)
  • Table 95. MEA Neurodegenerative Drugs, by Country USD Million (2018-2023)
  • Table 96. MEA Neurodegenerative Drugs, by Route of Administration USD Million (2018-2023)
  • Table 97. MEA Neurodegenerative Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 98. MEA Neurodegenerative Drugs, by Indication USD Million (2018-2023)
  • Table 99. MEA Neurodegenerative Drugs, by Drug Class USD Million (2018-2023)
  • Table 100. Middle East Neurodegenerative Drugs, by Route of Administration USD Million (2018-2023)
  • Table 101. Middle East Neurodegenerative Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 102. Middle East Neurodegenerative Drugs, by Indication USD Million (2018-2023)
  • Table 103. Middle East Neurodegenerative Drugs, by Drug Class USD Million (2018-2023)
  • Table 104. Africa Neurodegenerative Drugs, by Route of Administration USD Million (2018-2023)
  • Table 105. Africa Neurodegenerative Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 106. Africa Neurodegenerative Drugs, by Indication USD Million (2018-2023)
  • Table 107. Africa Neurodegenerative Drugs, by Drug Class USD Million (2018-2023)
  • Table 108. North America Neurodegenerative Drugs, by Country USD Million (2018-2023)
  • Table 109. North America Neurodegenerative Drugs, by Route of Administration USD Million (2018-2023)
  • Table 110. North America Neurodegenerative Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 111. North America Neurodegenerative Drugs, by Indication USD Million (2018-2023)
  • Table 112. North America Neurodegenerative Drugs, by Drug Class USD Million (2018-2023)
  • Table 113. United States Neurodegenerative Drugs, by Route of Administration USD Million (2018-2023)
  • Table 114. United States Neurodegenerative Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 115. United States Neurodegenerative Drugs, by Indication USD Million (2018-2023)
  • Table 116. United States Neurodegenerative Drugs, by Drug Class USD Million (2018-2023)
  • Table 117. Canada Neurodegenerative Drugs, by Route of Administration USD Million (2018-2023)
  • Table 118. Canada Neurodegenerative Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 119. Canada Neurodegenerative Drugs, by Indication USD Million (2018-2023)
  • Table 120. Canada Neurodegenerative Drugs, by Drug Class USD Million (2018-2023)
  • Table 121. Mexico Neurodegenerative Drugs, by Route of Administration USD Million (2018-2023)
  • Table 122. Mexico Neurodegenerative Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 123. Mexico Neurodegenerative Drugs, by Indication USD Million (2018-2023)
  • Table 124. Mexico Neurodegenerative Drugs, by Drug Class USD Million (2018-2023)
  • Table 125. Neurodegenerative Drugs Sales: by Route of Administration(K Tons)
  • Table 126. Neurodegenerative Drugs Sales Oral , by Region K Tons (2018-2023)
  • Table 127. Neurodegenerative Drugs Sales Injection , by Region K Tons (2018-2023)
  • Table 128. Neurodegenerative Drugs Sales Transdermal , by Region K Tons (2018-2023)
  • Table 129. Neurodegenerative Drugs Sales Others , by Region K Tons (2018-2023)
  • Table 130. Neurodegenerative Drugs Sales: by Distribution Channel(K Tons)
  • Table 131. Neurodegenerative Drugs Sales Retail Pharmacy , by Region K Tons (2018-2023)
  • Table 132. Neurodegenerative Drugs Sales Hospital Pharmacy , by Region K Tons (2018-2023)
  • Table 133. Neurodegenerative Drugs Sales Online Pharmacy , by Region K Tons (2018-2023)
  • Table 134. Neurodegenerative Drugs Sales: by Drug Class(K Tons)
  • Table 135. Neurodegenerative Drugs Sales Glutamate Regulators , by Region K Tons (2018-2023)
  • Table 136. Neurodegenerative Drugs Sales Decarboxylase Inhibitors , by Region K Tons (2018-2023)
  • Table 137. Neurodegenerative Drugs Sales Dopamine Agonist , by Region K Tons (2018-2023)
  • Table 138. Neurodegenerative Drugs Sales Cholinesterase Inhibitors , by Region K Tons (2018-2023)
  • Table 139. Neurodegenerative Drugs Sales Others , by Region K Tons (2018-2023)
  • Table 140. South America Neurodegenerative Drugs Sales, by Country K Tons (2018-2023)
  • Table 141. South America Neurodegenerative Drugs Sales, by Route of Administration K Tons (2018-2023)
  • Table 142. South America Neurodegenerative Drugs Sales, by Distribution Channel K Tons (2018-2023)
  • Table 143. South America Neurodegenerative Drugs Sales, by Indication K Tons (2018-2023)
  • Table 144. South America Neurodegenerative Drugs Sales, by Drug Class K Tons (2018-2023)
  • Table 145. Brazil Neurodegenerative Drugs Sales, by Route of Administration K Tons (2018-2023)
  • Table 146. Brazil Neurodegenerative Drugs Sales, by Distribution Channel K Tons (2018-2023)
  • Table 147. Brazil Neurodegenerative Drugs Sales, by Indication K Tons (2018-2023)
  • Table 148. Brazil Neurodegenerative Drugs Sales, by Drug Class K Tons (2018-2023)
  • Table 149. Argentina Neurodegenerative Drugs Sales, by Route of Administration K Tons (2018-2023)
  • Table 150. Argentina Neurodegenerative Drugs Sales, by Distribution Channel K Tons (2018-2023)
  • Table 151. Argentina Neurodegenerative Drugs Sales, by Indication K Tons (2018-2023)
  • Table 152. Argentina Neurodegenerative Drugs Sales, by Drug Class K Tons (2018-2023)
  • Table 153. Rest of South America Neurodegenerative Drugs Sales, by Route of Administration K Tons (2018-2023)
  • Table 154. Rest of South America Neurodegenerative Drugs Sales, by Distribution Channel K Tons (2018-2023)
  • Table 155. Rest of South America Neurodegenerative Drugs Sales, by Indication K Tons (2018-2023)
  • Table 156. Rest of South America Neurodegenerative Drugs Sales, by Drug Class K Tons (2018-2023)
  • Table 157. Asia Pacific Neurodegenerative Drugs Sales, by Country K Tons (2018-2023)
  • Table 158. Asia Pacific Neurodegenerative Drugs Sales, by Route of Administration K Tons (2018-2023)
  • Table 159. Asia Pacific Neurodegenerative Drugs Sales, by Distribution Channel K Tons (2018-2023)
  • Table 160. Asia Pacific Neurodegenerative Drugs Sales, by Indication K Tons (2018-2023)
  • Table 161. Asia Pacific Neurodegenerative Drugs Sales, by Drug Class K Tons (2018-2023)
  • Table 162. China Neurodegenerative Drugs Sales, by Route of Administration K Tons (2018-2023)
  • Table 163. China Neurodegenerative Drugs Sales, by Distribution Channel K Tons (2018-2023)
  • Table 164. China Neurodegenerative Drugs Sales, by Indication K Tons (2018-2023)
  • Table 165. China Neurodegenerative Drugs Sales, by Drug Class K Tons (2018-2023)
  • Table 166. Japan Neurodegenerative Drugs Sales, by Route of Administration K Tons (2018-2023)
  • Table 167. Japan Neurodegenerative Drugs Sales, by Distribution Channel K Tons (2018-2023)
  • Table 168. Japan Neurodegenerative Drugs Sales, by Indication K Tons (2018-2023)
  • Table 169. Japan Neurodegenerative Drugs Sales, by Drug Class K Tons (2018-2023)
  • Table 170. India Neurodegenerative Drugs Sales, by Route of Administration K Tons (2018-2023)
  • Table 171. India Neurodegenerative Drugs Sales, by Distribution Channel K Tons (2018-2023)
  • Table 172. India Neurodegenerative Drugs Sales, by Indication K Tons (2018-2023)
  • Table 173. India Neurodegenerative Drugs Sales, by Drug Class K Tons (2018-2023)
  • Table 174. South Korea Neurodegenerative Drugs Sales, by Route of Administration K Tons (2018-2023)
  • Table 175. South Korea Neurodegenerative Drugs Sales, by Distribution Channel K Tons (2018-2023)
  • Table 176. South Korea Neurodegenerative Drugs Sales, by Indication K Tons (2018-2023)
  • Table 177. South Korea Neurodegenerative Drugs Sales, by Drug Class K Tons (2018-2023)
  • Table 178. Taiwan Neurodegenerative Drugs Sales, by Route of Administration K Tons (2018-2023)
  • Table 179. Taiwan Neurodegenerative Drugs Sales, by Distribution Channel K Tons (2018-2023)
  • Table 180. Taiwan Neurodegenerative Drugs Sales, by Indication K Tons (2018-2023)
  • Table 181. Taiwan Neurodegenerative Drugs Sales, by Drug Class K Tons (2018-2023)
  • Table 182. Australia Neurodegenerative Drugs Sales, by Route of Administration K Tons (2018-2023)
  • Table 183. Australia Neurodegenerative Drugs Sales, by Distribution Channel K Tons (2018-2023)
  • Table 184. Australia Neurodegenerative Drugs Sales, by Indication K Tons (2018-2023)
  • Table 185. Australia Neurodegenerative Drugs Sales, by Drug Class K Tons (2018-2023)
  • Table 186. Rest of Asia-Pacific Neurodegenerative Drugs Sales, by Route of Administration K Tons (2018-2023)
  • Table 187. Rest of Asia-Pacific Neurodegenerative Drugs Sales, by Distribution Channel K Tons (2018-2023)
  • Table 188. Rest of Asia-Pacific Neurodegenerative Drugs Sales, by Indication K Tons (2018-2023)
  • Table 189. Rest of Asia-Pacific Neurodegenerative Drugs Sales, by Drug Class K Tons (2018-2023)
  • Table 190. Europe Neurodegenerative Drugs Sales, by Country K Tons (2018-2023)
  • Table 191. Europe Neurodegenerative Drugs Sales, by Route of Administration K Tons (2018-2023)
  • Table 192. Europe Neurodegenerative Drugs Sales, by Distribution Channel K Tons (2018-2023)
  • Table 193. Europe Neurodegenerative Drugs Sales, by Indication K Tons (2018-2023)
  • Table 194. Europe Neurodegenerative Drugs Sales, by Drug Class K Tons (2018-2023)
  • Table 195. Germany Neurodegenerative Drugs Sales, by Route of Administration K Tons (2018-2023)
  • Table 196. Germany Neurodegenerative Drugs Sales, by Distribution Channel K Tons (2018-2023)
  • Table 197. Germany Neurodegenerative Drugs Sales, by Indication K Tons (2018-2023)
  • Table 198. Germany Neurodegenerative Drugs Sales, by Drug Class K Tons (2018-2023)
  • Table 199. France Neurodegenerative Drugs Sales, by Route of Administration K Tons (2018-2023)
  • Table 200. France Neurodegenerative Drugs Sales, by Distribution Channel K Tons (2018-2023)
  • Table 201. France Neurodegenerative Drugs Sales, by Indication K Tons (2018-2023)
  • Table 202. France Neurodegenerative Drugs Sales, by Drug Class K Tons (2018-2023)
  • Table 203. Italy Neurodegenerative Drugs Sales, by Route of Administration K Tons (2018-2023)
  • Table 204. Italy Neurodegenerative Drugs Sales, by Distribution Channel K Tons (2018-2023)
  • Table 205. Italy Neurodegenerative Drugs Sales, by Indication K Tons (2018-2023)
  • Table 206. Italy Neurodegenerative Drugs Sales, by Drug Class K Tons (2018-2023)
  • Table 207. United Kingdom Neurodegenerative Drugs Sales, by Route of Administration K Tons (2018-2023)
  • Table 208. United Kingdom Neurodegenerative Drugs Sales, by Distribution Channel K Tons (2018-2023)
  • Table 209. United Kingdom Neurodegenerative Drugs Sales, by Indication K Tons (2018-2023)
  • Table 210. United Kingdom Neurodegenerative Drugs Sales, by Drug Class K Tons (2018-2023)
  • Table 211. Netherlands Neurodegenerative Drugs Sales, by Route of Administration K Tons (2018-2023)
  • Table 212. Netherlands Neurodegenerative Drugs Sales, by Distribution Channel K Tons (2018-2023)
  • Table 213. Netherlands Neurodegenerative Drugs Sales, by Indication K Tons (2018-2023)
  • Table 214. Netherlands Neurodegenerative Drugs Sales, by Drug Class K Tons (2018-2023)
  • Table 215. Rest of Europe Neurodegenerative Drugs Sales, by Route of Administration K Tons (2018-2023)
  • Table 216. Rest of Europe Neurodegenerative Drugs Sales, by Distribution Channel K Tons (2018-2023)
  • Table 217. Rest of Europe Neurodegenerative Drugs Sales, by Indication K Tons (2018-2023)
  • Table 218. Rest of Europe Neurodegenerative Drugs Sales, by Drug Class K Tons (2018-2023)
  • Table 219. MEA Neurodegenerative Drugs Sales, by Country K Tons (2018-2023)
  • Table 220. MEA Neurodegenerative Drugs Sales, by Route of Administration K Tons (2018-2023)
  • Table 221. MEA Neurodegenerative Drugs Sales, by Distribution Channel K Tons (2018-2023)
  • Table 222. MEA Neurodegenerative Drugs Sales, by Indication K Tons (2018-2023)
  • Table 223. MEA Neurodegenerative Drugs Sales, by Drug Class K Tons (2018-2023)
  • Table 224. Middle East Neurodegenerative Drugs Sales, by Route of Administration K Tons (2018-2023)
  • Table 225. Middle East Neurodegenerative Drugs Sales, by Distribution Channel K Tons (2018-2023)
  • Table 226. Middle East Neurodegenerative Drugs Sales, by Indication K Tons (2018-2023)
  • Table 227. Middle East Neurodegenerative Drugs Sales, by Drug Class K Tons (2018-2023)
  • Table 228. Africa Neurodegenerative Drugs Sales, by Route of Administration K Tons (2018-2023)
  • Table 229. Africa Neurodegenerative Drugs Sales, by Distribution Channel K Tons (2018-2023)
  • Table 230. Africa Neurodegenerative Drugs Sales, by Indication K Tons (2018-2023)
  • Table 231. Africa Neurodegenerative Drugs Sales, by Drug Class K Tons (2018-2023)
  • Table 232. North America Neurodegenerative Drugs Sales, by Country K Tons (2018-2023)
  • Table 233. North America Neurodegenerative Drugs Sales, by Route of Administration K Tons (2018-2023)
  • Table 234. North America Neurodegenerative Drugs Sales, by Distribution Channel K Tons (2018-2023)
  • Table 235. North America Neurodegenerative Drugs Sales, by Indication K Tons (2018-2023)
  • Table 236. North America Neurodegenerative Drugs Sales, by Drug Class K Tons (2018-2023)
  • Table 237. United States Neurodegenerative Drugs Sales, by Route of Administration K Tons (2018-2023)
  • Table 238. United States Neurodegenerative Drugs Sales, by Distribution Channel K Tons (2018-2023)
  • Table 239. United States Neurodegenerative Drugs Sales, by Indication K Tons (2018-2023)
  • Table 240. United States Neurodegenerative Drugs Sales, by Drug Class K Tons (2018-2023)
  • Table 241. Canada Neurodegenerative Drugs Sales, by Route of Administration K Tons (2018-2023)
  • Table 242. Canada Neurodegenerative Drugs Sales, by Distribution Channel K Tons (2018-2023)
  • Table 243. Canada Neurodegenerative Drugs Sales, by Indication K Tons (2018-2023)
  • Table 244. Canada Neurodegenerative Drugs Sales, by Drug Class K Tons (2018-2023)
  • Table 245. Mexico Neurodegenerative Drugs Sales, by Route of Administration K Tons (2018-2023)
  • Table 246. Mexico Neurodegenerative Drugs Sales, by Distribution Channel K Tons (2018-2023)
  • Table 247. Mexico Neurodegenerative Drugs Sales, by Indication K Tons (2018-2023)
  • Table 248. Mexico Neurodegenerative Drugs Sales, by Drug Class K Tons (2018-2023)
  • Table 249. Company Basic Information, Sales Area and Its Competitors
  • Table 250. Company Basic Information, Sales Area and Its Competitors
  • Table 251. Company Basic Information, Sales Area and Its Competitors
  • Table 252. Company Basic Information, Sales Area and Its Competitors
  • Table 253. Company Basic Information, Sales Area and Its Competitors
  • Table 254. Company Basic Information, Sales Area and Its Competitors
  • Table 255. Company Basic Information, Sales Area and Its Competitors
  • Table 256. Company Basic Information, Sales Area and Its Competitors
  • Table 257. Company Basic Information, Sales Area and Its Competitors
  • Table 258. Company Basic Information, Sales Area and Its Competitors
  • Table 259. Neurodegenerative Drugs: by Route of Administration(USD Million)
  • Table 260. Neurodegenerative Drugs Oral , by Region USD Million (2025-2030)
  • Table 261. Neurodegenerative Drugs Injection , by Region USD Million (2025-2030)
  • Table 262. Neurodegenerative Drugs Transdermal , by Region USD Million (2025-2030)
  • Table 263. Neurodegenerative Drugs Others , by Region USD Million (2025-2030)
  • Table 264. Neurodegenerative Drugs: by Distribution Channel(USD Million)
  • Table 265. Neurodegenerative Drugs Retail Pharmacy , by Region USD Million (2025-2030)
  • Table 266. Neurodegenerative Drugs Hospital Pharmacy , by Region USD Million (2025-2030)
  • Table 267. Neurodegenerative Drugs Online Pharmacy , by Region USD Million (2025-2030)
  • Table 268. Neurodegenerative Drugs: by Drug Class(USD Million)
  • Table 269. Neurodegenerative Drugs Glutamate Regulators , by Region USD Million (2025-2030)
  • Table 270. Neurodegenerative Drugs Decarboxylase Inhibitors , by Region USD Million (2025-2030)
  • Table 271. Neurodegenerative Drugs Dopamine Agonist , by Region USD Million (2025-2030)
  • Table 272. Neurodegenerative Drugs Cholinesterase Inhibitors , by Region USD Million (2025-2030)
  • Table 273. Neurodegenerative Drugs Others , by Region USD Million (2025-2030)
  • Table 274. South America Neurodegenerative Drugs, by Country USD Million (2025-2030)
  • Table 275. South America Neurodegenerative Drugs, by Route of Administration USD Million (2025-2030)
  • Table 276. South America Neurodegenerative Drugs, by Distribution Channel USD Million (2025-2030)
  • Table 277. South America Neurodegenerative Drugs, by Indication USD Million (2025-2030)
  • Table 278. South America Neurodegenerative Drugs, by Drug Class USD Million (2025-2030)
  • Table 279. Brazil Neurodegenerative Drugs, by Route of Administration USD Million (2025-2030)
  • Table 280. Brazil Neurodegenerative Drugs, by Distribution Channel USD Million (2025-2030)
  • Table 281. Brazil Neurodegenerative Drugs, by Indication USD Million (2025-2030)
  • Table 282. Brazil Neurodegenerative Drugs, by Drug Class USD Million (2025-2030)
  • Table 283. Argentina Neurodegenerative Drugs, by Route of Administration USD Million (2025-2030)
  • Table 284. Argentina Neurodegenerative Drugs, by Distribution Channel USD Million (2025-2030)
  • Table 285. Argentina Neurodegenerative Drugs, by Indication USD Million (2025-2030)
  • Table 286. Argentina Neurodegenerative Drugs, by Drug Class USD Million (2025-2030)
  • Table 287. Rest of South America Neurodegenerative Drugs, by Route of Administration USD Million (2025-2030)
  • Table 288. Rest of South America Neurodegenerative Drugs, by Distribution Channel USD Million (2025-2030)
  • Table 289. Rest of South America Neurodegenerative Drugs, by Indication USD Million (2025-2030)
  • Table 290. Rest of South America Neurodegenerative Drugs, by Drug Class USD Million (2025-2030)
  • Table 291. Asia Pacific Neurodegenerative Drugs, by Country USD Million (2025-2030)
  • Table 292. Asia Pacific Neurodegenerative Drugs, by Route of Administration USD Million (2025-2030)
  • Table 293. Asia Pacific Neurodegenerative Drugs, by Distribution Channel USD Million (2025-2030)
  • Table 294. Asia Pacific Neurodegenerative Drugs, by Indication USD Million (2025-2030)
  • Table 295. Asia Pacific Neurodegenerative Drugs, by Drug Class USD Million (2025-2030)
  • Table 296. China Neurodegenerative Drugs, by Route of Administration USD Million (2025-2030)
  • Table 297. China Neurodegenerative Drugs, by Distribution Channel USD Million (2025-2030)
  • Table 298. China Neurodegenerative Drugs, by Indication USD Million (2025-2030)
  • Table 299. China Neurodegenerative Drugs, by Drug Class USD Million (2025-2030)
  • Table 300. Japan Neurodegenerative Drugs, by Route of Administration USD Million (2025-2030)
  • Table 301. Japan Neurodegenerative Drugs, by Distribution Channel USD Million (2025-2030)
  • Table 302. Japan Neurodegenerative Drugs, by Indication USD Million (2025-2030)
  • Table 303. Japan Neurodegenerative Drugs, by Drug Class USD Million (2025-2030)
  • Table 304. India Neurodegenerative Drugs, by Route of Administration USD Million (2025-2030)
  • Table 305. India Neurodegenerative Drugs, by Distribution Channel USD Million (2025-2030)
  • Table 306. India Neurodegenerative Drugs, by Indication USD Million (2025-2030)
  • Table 307. India Neurodegenerative Drugs, by Drug Class USD Million (2025-2030)
  • Table 308. South Korea Neurodegenerative Drugs, by Route of Administration USD Million (2025-2030)
  • Table 309. South Korea Neurodegenerative Drugs, by Distribution Channel USD Million (2025-2030)
  • Table 310. South Korea Neurodegenerative Drugs, by Indication USD Million (2025-2030)
  • Table 311. South Korea Neurodegenerative Drugs, by Drug Class USD Million (2025-2030)
  • Table 312. Taiwan Neurodegenerative Drugs, by Route of Administration USD Million (2025-2030)
  • Table 313. Taiwan Neurodegenerative Drugs, by Distribution Channel USD Million (2025-2030)
  • Table 314. Taiwan Neurodegenerative Drugs, by Indication USD Million (2025-2030)
  • Table 315. Taiwan Neurodegenerative Drugs, by Drug Class USD Million (2025-2030)
  • Table 316. Australia Neurodegenerative Drugs, by Route of Administration USD Million (2025-2030)
  • Table 317. Australia Neurodegenerative Drugs, by Distribution Channel USD Million (2025-2030)
  • Table 318. Australia Neurodegenerative Drugs, by Indication USD Million (2025-2030)
  • Table 319. Australia Neurodegenerative Drugs, by Drug Class USD Million (2025-2030)
  • Table 320. Rest of Asia-Pacific Neurodegenerative Drugs, by Route of Administration USD Million (2025-2030)
  • Table 321. Rest of Asia-Pacific Neurodegenerative Drugs, by Distribution Channel USD Million (2025-2030)
  • Table 322. Rest of Asia-Pacific Neurodegenerative Drugs, by Indication USD Million (2025-2030)
  • Table 323. Rest of Asia-Pacific Neurodegenerative Drugs, by Drug Class USD Million (2025-2030)
  • Table 324. Europe Neurodegenerative Drugs, by Country USD Million (2025-2030)
  • Table 325. Europe Neurodegenerative Drugs, by Route of Administration USD Million (2025-2030)
  • Table 326. Europe Neurodegenerative Drugs, by Distribution Channel USD Million (2025-2030)
  • Table 327. Europe Neurodegenerative Drugs, by Indication USD Million (2025-2030)
  • Table 328. Europe Neurodegenerative Drugs, by Drug Class USD Million (2025-2030)
  • Table 329. Germany Neurodegenerative Drugs, by Route of Administration USD Million (2025-2030)
  • Table 330. Germany Neurodegenerative Drugs, by Distribution Channel USD Million (2025-2030)
  • Table 331. Germany Neurodegenerative Drugs, by Indication USD Million (2025-2030)
  • Table 332. Germany Neurodegenerative Drugs, by Drug Class USD Million (2025-2030)
  • Table 333. France Neurodegenerative Drugs, by Route of Administration USD Million (2025-2030)
  • Table 334. France Neurodegenerative Drugs, by Distribution Channel USD Million (2025-2030)
  • Table 335. France Neurodegenerative Drugs, by Indication USD Million (2025-2030)
  • Table 336. France Neurodegenerative Drugs, by Drug Class USD Million (2025-2030)
  • Table 337. Italy Neurodegenerative Drugs, by Route of Administration USD Million (2025-2030)
  • Table 338. Italy Neurodegenerative Drugs, by Distribution Channel USD Million (2025-2030)
  • Table 339. Italy Neurodegenerative Drugs, by Indication USD Million (2025-2030)
  • Table 340. Italy Neurodegenerative Drugs, by Drug Class USD Million (2025-2030)
  • Table 341. United Kingdom Neurodegenerative Drugs, by Route of Administration USD Million (2025-2030)
  • Table 342. United Kingdom Neurodegenerative Drugs, by Distribution Channel USD Million (2025-2030)
  • Table 343. United Kingdom Neurodegenerative Drugs, by Indication USD Million (2025-2030)
  • Table 344. United Kingdom Neurodegenerative Drugs, by Drug Class USD Million (2025-2030)
  • Table 345. Netherlands Neurodegenerative Drugs, by Route of Administration USD Million (2025-2030)
  • Table 346. Netherlands Neurodegenerative Drugs, by Distribution Channel USD Million (2025-2030)
  • Table 347. Netherlands Neurodegenerative Drugs, by Indication USD Million (2025-2030)
  • Table 348. Netherlands Neurodegenerative Drugs, by Drug Class USD Million (2025-2030)
  • Table 349. Rest of Europe Neurodegenerative Drugs, by Route of Administration USD Million (2025-2030)
  • Table 350. Rest of Europe Neurodegenerative Drugs, by Distribution Channel USD Million (2025-2030)
  • Table 351. Rest of Europe Neurodegenerative Drugs, by Indication USD Million (2025-2030)
  • Table 352. Rest of Europe Neurodegenerative Drugs, by Drug Class USD Million (2025-2030)
  • Table 353. MEA Neurodegenerative Drugs, by Country USD Million (2025-2030)
  • Table 354. MEA Neurodegenerative Drugs, by Route of Administration USD Million (2025-2030)
  • Table 355. MEA Neurodegenerative Drugs, by Distribution Channel USD Million (2025-2030)
  • Table 356. MEA Neurodegenerative Drugs, by Indication USD Million (2025-2030)
  • Table 357. MEA Neurodegenerative Drugs, by Drug Class USD Million (2025-2030)
  • Table 358. Middle East Neurodegenerative Drugs, by Route of Administration USD Million (2025-2030)
  • Table 359. Middle East Neurodegenerative Drugs, by Distribution Channel USD Million (2025-2030)
  • Table 360. Middle East Neurodegenerative Drugs, by Indication USD Million (2025-2030)
  • Table 361. Middle East Neurodegenerative Drugs, by Drug Class USD Million (2025-2030)
  • Table 362. Africa Neurodegenerative Drugs, by Route of Administration USD Million (2025-2030)
  • Table 363. Africa Neurodegenerative Drugs, by Distribution Channel USD Million (2025-2030)
  • Table 364. Africa Neurodegenerative Drugs, by Indication USD Million (2025-2030)
  • Table 365. Africa Neurodegenerative Drugs, by Drug Class USD Million (2025-2030)
  • Table 366. North America Neurodegenerative Drugs, by Country USD Million (2025-2030)
  • Table 367. North America Neurodegenerative Drugs, by Route of Administration USD Million (2025-2030)
  • Table 368. North America Neurodegenerative Drugs, by Distribution Channel USD Million (2025-2030)
  • Table 369. North America Neurodegenerative Drugs, by Indication USD Million (2025-2030)
  • Table 370. North America Neurodegenerative Drugs, by Drug Class USD Million (2025-2030)
  • Table 371. United States Neurodegenerative Drugs, by Route of Administration USD Million (2025-2030)
  • Table 372. United States Neurodegenerative Drugs, by Distribution Channel USD Million (2025-2030)
  • Table 373. United States Neurodegenerative Drugs, by Indication USD Million (2025-2030)
  • Table 374. United States Neurodegenerative Drugs, by Drug Class USD Million (2025-2030)
  • Table 375. Canada Neurodegenerative Drugs, by Route of Administration USD Million (2025-2030)
  • Table 376. Canada Neurodegenerative Drugs, by Distribution Channel USD Million (2025-2030)
  • Table 377. Canada Neurodegenerative Drugs, by Indication USD Million (2025-2030)
  • Table 378. Canada Neurodegenerative Drugs, by Drug Class USD Million (2025-2030)
  • Table 379. Mexico Neurodegenerative Drugs, by Route of Administration USD Million (2025-2030)
  • Table 380. Mexico Neurodegenerative Drugs, by Distribution Channel USD Million (2025-2030)
  • Table 381. Mexico Neurodegenerative Drugs, by Indication USD Million (2025-2030)
  • Table 382. Mexico Neurodegenerative Drugs, by Drug Class USD Million (2025-2030)
  • Table 383. Neurodegenerative Drugs Sales: by Route of Administration(K Tons)
  • Table 384. Neurodegenerative Drugs Sales Oral , by Region K Tons (2025-2030)
  • Table 385. Neurodegenerative Drugs Sales Injection , by Region K Tons (2025-2030)
  • Table 386. Neurodegenerative Drugs Sales Transdermal , by Region K Tons (2025-2030)
  • Table 387. Neurodegenerative Drugs Sales Others , by Region K Tons (2025-2030)
  • Table 388. Neurodegenerative Drugs Sales: by Distribution Channel(K Tons)
  • Table 389. Neurodegenerative Drugs Sales Retail Pharmacy , by Region K Tons (2025-2030)
  • Table 390. Neurodegenerative Drugs Sales Hospital Pharmacy , by Region K Tons (2025-2030)
  • Table 391. Neurodegenerative Drugs Sales Online Pharmacy , by Region K Tons (2025-2030)
  • Table 392. Neurodegenerative Drugs Sales: by Drug Class(K Tons)
  • Table 393. Neurodegenerative Drugs Sales Glutamate Regulators , by Region K Tons (2025-2030)
  • Table 394. Neurodegenerative Drugs Sales Decarboxylase Inhibitors , by Region K Tons (2025-2030)
  • Table 395. Neurodegenerative Drugs Sales Dopamine Agonist , by Region K Tons (2025-2030)
  • Table 396. Neurodegenerative Drugs Sales Cholinesterase Inhibitors , by Region K Tons (2025-2030)
  • Table 397. Neurodegenerative Drugs Sales Others , by Region K Tons (2025-2030)
  • Table 398. South America Neurodegenerative Drugs Sales, by Country K Tons (2025-2030)
  • Table 399. South America Neurodegenerative Drugs Sales, by Route of Administration K Tons (2025-2030)
  • Table 400. South America Neurodegenerative Drugs Sales, by Distribution Channel K Tons (2025-2030)
  • Table 401. South America Neurodegenerative Drugs Sales, by Indication K Tons (2025-2030)
  • Table 402. South America Neurodegenerative Drugs Sales, by Drug Class K Tons (2025-2030)
  • Table 403. Brazil Neurodegenerative Drugs Sales, by Route of Administration K Tons (2025-2030)
  • Table 404. Brazil Neurodegenerative Drugs Sales, by Distribution Channel K Tons (2025-2030)
  • Table 405. Brazil Neurodegenerative Drugs Sales, by Indication K Tons (2025-2030)
  • Table 406. Brazil Neurodegenerative Drugs Sales, by Drug Class K Tons (2025-2030)
  • Table 407. Argentina Neurodegenerative Drugs Sales, by Route of Administration K Tons (2025-2030)
  • Table 408. Argentina Neurodegenerative Drugs Sales, by Distribution Channel K Tons (2025-2030)
  • Table 409. Argentina Neurodegenerative Drugs Sales, by Indication K Tons (2025-2030)
  • Table 410. Argentina Neurodegenerative Drugs Sales, by Drug Class K Tons (2025-2030)
  • Table 411. Rest of South America Neurodegenerative Drugs Sales, by Route of Administration K Tons (2025-2030)
  • Table 412. Rest of South America Neurodegenerative Drugs Sales, by Distribution Channel K Tons (2025-2030)
  • Table 413. Rest of South America Neurodegenerative Drugs Sales, by Indication K Tons (2025-2030)
  • Table 414. Rest of South America Neurodegenerative Drugs Sales, by Drug Class K Tons (2025-2030)
  • Table 415. Asia Pacific Neurodegenerative Drugs Sales, by Country K Tons (2025-2030)
  • Table 416. Asia Pacific Neurodegenerative Drugs Sales, by Route of Administration K Tons (2025-2030)
  • Table 417. Asia Pacific Neurodegenerative Drugs Sales, by Distribution Channel K Tons (2025-2030)
  • Table 418. Asia Pacific Neurodegenerative Drugs Sales, by Indication K Tons (2025-2030)
  • Table 419. Asia Pacific Neurodegenerative Drugs Sales, by Drug Class K Tons (2025-2030)
  • Table 420. China Neurodegenerative Drugs Sales, by Route of Administration K Tons (2025-2030)
  • Table 421. China Neurodegenerative Drugs Sales, by Distribution Channel K Tons (2025-2030)
  • Table 422. China Neurodegenerative Drugs Sales, by Indication K Tons (2025-2030)
  • Table 423. China Neurodegenerative Drugs Sales, by Drug Class K Tons (2025-2030)
  • Table 424. Japan Neurodegenerative Drugs Sales, by Route of Administration K Tons (2025-2030)
  • Table 425. Japan Neurodegenerative Drugs Sales, by Distribution Channel K Tons (2025-2030)
  • Table 426. Japan Neurodegenerative Drugs Sales, by Indication K Tons (2025-2030)
  • Table 427. Japan Neurodegenerative Drugs Sales, by Drug Class K Tons (2025-2030)
  • Table 428. India Neurodegenerative Drugs Sales, by Route of Administration K Tons (2025-2030)
  • Table 429. India Neurodegenerative Drugs Sales, by Distribution Channel K Tons (2025-2030)
  • Table 430. India Neurodegenerative Drugs Sales, by Indication K Tons (2025-2030)
  • Table 431. India Neurodegenerative Drugs Sales, by Drug Class K Tons (2025-2030)
  • Table 432. South Korea Neurodegenerative Drugs Sales, by Route of Administration K Tons (2025-2030)
  • Table 433. South Korea Neurodegenerative Drugs Sales, by Distribution Channel K Tons (2025-2030)
  • Table 434. South Korea Neurodegenerative Drugs Sales, by Indication K Tons (2025-2030)
  • Table 435. South Korea Neurodegenerative Drugs Sales, by Drug Class K Tons (2025-2030)
  • Table 436. Taiwan Neurodegenerative Drugs Sales, by Route of Administration K Tons (2025-2030)
  • Table 437. Taiwan Neurodegenerative Drugs Sales, by Distribution Channel K Tons (2025-2030)
  • Table 438. Taiwan Neurodegenerative Drugs Sales, by Indication K Tons (2025-2030)
  • Table 439. Taiwan Neurodegenerative Drugs Sales, by Drug Class K Tons (2025-2030)
  • Table 440. Australia Neurodegenerative Drugs Sales, by Route of Administration K Tons (2025-2030)
  • Table 441. Australia Neurodegenerative Drugs Sales, by Distribution Channel K Tons (2025-2030)
  • Table 442. Australia Neurodegenerative Drugs Sales, by Indication K Tons (2025-2030)
  • Table 443. Australia Neurodegenerative Drugs Sales, by Drug Class K Tons (2025-2030)
  • Table 444. Rest of Asia-Pacific Neurodegenerative Drugs Sales, by Route of Administration K Tons (2025-2030)
  • Table 445. Rest of Asia-Pacific Neurodegenerative Drugs Sales, by Distribution Channel K Tons (2025-2030)
  • Table 446. Rest of Asia-Pacific Neurodegenerative Drugs Sales, by Indication K Tons (2025-2030)
  • Table 447. Rest of Asia-Pacific Neurodegenerative Drugs Sales, by Drug Class K Tons (2025-2030)
  • Table 448. Europe Neurodegenerative Drugs Sales, by Country K Tons (2025-2030)
  • Table 449. Europe Neurodegenerative Drugs Sales, by Route of Administration K Tons (2025-2030)
  • Table 450. Europe Neurodegenerative Drugs Sales, by Distribution Channel K Tons (2025-2030)
  • Table 451. Europe Neurodegenerative Drugs Sales, by Indication K Tons (2025-2030)
  • Table 452. Europe Neurodegenerative Drugs Sales, by Drug Class K Tons (2025-2030)
  • Table 453. Germany Neurodegenerative Drugs Sales, by Route of Administration K Tons (2025-2030)
  • Table 454. Germany Neurodegenerative Drugs Sales, by Distribution Channel K Tons (2025-2030)
  • Table 455. Germany Neurodegenerative Drugs Sales, by Indication K Tons (2025-2030)
  • Table 456. Germany Neurodegenerative Drugs Sales, by Drug Class K Tons (2025-2030)
  • Table 457. France Neurodegenerative Drugs Sales, by Route of Administration K Tons (2025-2030)
  • Table 458. France Neurodegenerative Drugs Sales, by Distribution Channel K Tons (2025-2030)
  • Table 459. France Neurodegenerative Drugs Sales, by Indication K Tons (2025-2030)
  • Table 460. France Neurodegenerative Drugs Sales, by Drug Class K Tons (2025-2030)
  • Table 461. Italy Neurodegenerative Drugs Sales, by Route of Administration K Tons (2025-2030)
  • Table 462. Italy Neurodegenerative Drugs Sales, by Distribution Channel K Tons (2025-2030)
  • Table 463. Italy Neurodegenerative Drugs Sales, by Indication K Tons (2025-2030)
  • Table 464. Italy Neurodegenerative Drugs Sales, by Drug Class K Tons (2025-2030)
  • Table 465. United Kingdom Neurodegenerative Drugs Sales, by Route of Administration K Tons (2025-2030)
  • Table 466. United Kingdom Neurodegenerative Drugs Sales, by Distribution Channel K Tons (2025-2030)
  • Table 467. United Kingdom Neurodegenerative Drugs Sales, by Indication K Tons (2025-2030)
  • Table 468. United Kingdom Neurodegenerative Drugs Sales, by Drug Class K Tons (2025-2030)
  • Table 469. Netherlands Neurodegenerative Drugs Sales, by Route of Administration K Tons (2025-2030)
  • Table 470. Netherlands Neurodegenerative Drugs Sales, by Distribution Channel K Tons (2025-2030)
  • Table 471. Netherlands Neurodegenerative Drugs Sales, by Indication K Tons (2025-2030)
  • Table 472. Netherlands Neurodegenerative Drugs Sales, by Drug Class K Tons (2025-2030)
  • Table 473. Rest of Europe Neurodegenerative Drugs Sales, by Route of Administration K Tons (2025-2030)
  • Table 474. Rest of Europe Neurodegenerative Drugs Sales, by Distribution Channel K Tons (2025-2030)
  • Table 475. Rest of Europe Neurodegenerative Drugs Sales, by Indication K Tons (2025-2030)
  • Table 476. Rest of Europe Neurodegenerative Drugs Sales, by Drug Class K Tons (2025-2030)
  • Table 477. MEA Neurodegenerative Drugs Sales, by Country K Tons (2025-2030)
  • Table 478. MEA Neurodegenerative Drugs Sales, by Route of Administration K Tons (2025-2030)
  • Table 479. MEA Neurodegenerative Drugs Sales, by Distribution Channel K Tons (2025-2030)
  • Table 480. MEA Neurodegenerative Drugs Sales, by Indication K Tons (2025-2030)
  • Table 481. MEA Neurodegenerative Drugs Sales, by Drug Class K Tons (2025-2030)
  • Table 482. Middle East Neurodegenerative Drugs Sales, by Route of Administration K Tons (2025-2030)
  • Table 483. Middle East Neurodegenerative Drugs Sales, by Distribution Channel K Tons (2025-2030)
  • Table 484. Middle East Neurodegenerative Drugs Sales, by Indication K Tons (2025-2030)
  • Table 485. Middle East Neurodegenerative Drugs Sales, by Drug Class K Tons (2025-2030)
  • Table 486. Africa Neurodegenerative Drugs Sales, by Route of Administration K Tons (2025-2030)
  • Table 487. Africa Neurodegenerative Drugs Sales, by Distribution Channel K Tons (2025-2030)
  • Table 488. Africa Neurodegenerative Drugs Sales, by Indication K Tons (2025-2030)
  • Table 489. Africa Neurodegenerative Drugs Sales, by Drug Class K Tons (2025-2030)
  • Table 490. North America Neurodegenerative Drugs Sales, by Country K Tons (2025-2030)
  • Table 491. North America Neurodegenerative Drugs Sales, by Route of Administration K Tons (2025-2030)
  • Table 492. North America Neurodegenerative Drugs Sales, by Distribution Channel K Tons (2025-2030)
  • Table 493. North America Neurodegenerative Drugs Sales, by Indication K Tons (2025-2030)
  • Table 494. North America Neurodegenerative Drugs Sales, by Drug Class K Tons (2025-2030)
  • Table 495. United States Neurodegenerative Drugs Sales, by Route of Administration K Tons (2025-2030)
  • Table 496. United States Neurodegenerative Drugs Sales, by Distribution Channel K Tons (2025-2030)
  • Table 497. United States Neurodegenerative Drugs Sales, by Indication K Tons (2025-2030)
  • Table 498. United States Neurodegenerative Drugs Sales, by Drug Class K Tons (2025-2030)
  • Table 499. Canada Neurodegenerative Drugs Sales, by Route of Administration K Tons (2025-2030)
  • Table 500. Canada Neurodegenerative Drugs Sales, by Distribution Channel K Tons (2025-2030)
  • Table 501. Canada Neurodegenerative Drugs Sales, by Indication K Tons (2025-2030)
  • Table 502. Canada Neurodegenerative Drugs Sales, by Drug Class K Tons (2025-2030)
  • Table 503. Mexico Neurodegenerative Drugs Sales, by Route of Administration K Tons (2025-2030)
  • Table 504. Mexico Neurodegenerative Drugs Sales, by Distribution Channel K Tons (2025-2030)
  • Table 505. Mexico Neurodegenerative Drugs Sales, by Indication K Tons (2025-2030)
  • Table 506. Mexico Neurodegenerative Drugs Sales, by Drug Class K Tons (2025-2030)
  • Table 507. Research Programs/Design for This Report
  • Table 508. Key Data Information from Secondary Sources
  • Table 509. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Neurodegenerative Drugs: by Route of Administration USD Million (2018-2023)
  • Figure 5. Global Neurodegenerative Drugs: by Distribution Channel USD Million (2018-2023)
  • Figure 6. Global Neurodegenerative Drugs: by Drug Class USD Million (2018-2023)
  • Figure 7. South America Neurodegenerative Drugs Share (%), by Country
  • Figure 8. Asia Pacific Neurodegenerative Drugs Share (%), by Country
  • Figure 9. Europe Neurodegenerative Drugs Share (%), by Country
  • Figure 10. MEA Neurodegenerative Drugs Share (%), by Country
  • Figure 11. North America Neurodegenerative Drugs Share (%), by Country
  • Figure 12. Global Neurodegenerative Drugs: by Route of Administration K Tons (2018-2023)
  • Figure 13. Global Neurodegenerative Drugs: by Distribution Channel K Tons (2018-2023)
  • Figure 14. Global Neurodegenerative Drugs: by Drug Class K Tons (2018-2023)
  • Figure 15. South America Neurodegenerative Drugs Share (%), by Country
  • Figure 16. Asia Pacific Neurodegenerative Drugs Share (%), by Country
  • Figure 17. Europe Neurodegenerative Drugs Share (%), by Country
  • Figure 18. MEA Neurodegenerative Drugs Share (%), by Country
  • Figure 19. North America Neurodegenerative Drugs Share (%), by Country
  • Figure 20. Global Neurodegenerative Drugs share by Players 2023 (%)
  • Figure 21. Global Neurodegenerative Drugs share by Players (Top 3) 2023(%)
  • Figure 22. Global Neurodegenerative Drugs share by Players (Top 5) 2023(%)
  • Figure 23. BCG Matrix for key Companies
  • Figure 24. AbbVie Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 25. AbbVie Inc. (United States) Revenue: by Geography 2023
  • Figure 26. GSK plc (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 27. GSK plc (United Kingdom) Revenue: by Geography 2023
  • Figure 28. Johnson & Johnson Services, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 29. Johnson & Johnson Services, Inc. (United States) Revenue: by Geography 2023
  • Figure 30. Biogen (United States) Revenue, Net Income and Gross profit
  • Figure 31. Biogen (United States) Revenue: by Geography 2023
  • Figure 32. Merck & Co., Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 33. Merck & Co., Inc. (United States) Revenue: by Geography 2023
  • Figure 34. Novartis AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 35. Novartis AG (Switzerland) Revenue: by Geography 2023
  • Figure 36. Bristol-Myers Squibb (United States) Revenue, Net Income and Gross profit
  • Figure 37. Bristol-Myers Squibb (United States) Revenue: by Geography 2023
  • Figure 38. Lilly (United States) Revenue, Net Income and Gross profit
  • Figure 39. Lilly (United States) Revenue: by Geography 2023
  • Figure 40. Eisai Co., Ltd. (Japan) Revenue, Net Income and Gross profit
  • Figure 41. Eisai Co., Ltd. (Japan) Revenue: by Geography 2023
  • Figure 42. F. Hoffmann-La Roche Ltd. (Switzerland) Revenue, Net Income and Gross profit
  • Figure 43. F. Hoffmann-La Roche Ltd. (Switzerland) Revenue: by Geography 2023
  • Figure 44. Global Neurodegenerative Drugs: by Route of Administration USD Million (2025-2030)
  • Figure 45. Global Neurodegenerative Drugs: by Distribution Channel USD Million (2025-2030)
  • Figure 46. Global Neurodegenerative Drugs: by Drug Class USD Million (2025-2030)
  • Figure 47. South America Neurodegenerative Drugs Share (%), by Country
  • Figure 48. Asia Pacific Neurodegenerative Drugs Share (%), by Country
  • Figure 49. Europe Neurodegenerative Drugs Share (%), by Country
  • Figure 50. MEA Neurodegenerative Drugs Share (%), by Country
  • Figure 51. North America Neurodegenerative Drugs Share (%), by Country
  • Figure 52. Global Neurodegenerative Drugs: by Route of Administration K Tons (2025-2030)
  • Figure 53. Global Neurodegenerative Drugs: by Distribution Channel K Tons (2025-2030)
  • Figure 54. Global Neurodegenerative Drugs: by Drug Class K Tons (2025-2030)
  • Figure 55. South America Neurodegenerative Drugs Share (%), by Country
  • Figure 56. Asia Pacific Neurodegenerative Drugs Share (%), by Country
  • Figure 57. Europe Neurodegenerative Drugs Share (%), by Country
  • Figure 58. MEA Neurodegenerative Drugs Share (%), by Country
  • Figure 59. North America Neurodegenerative Drugs Share (%), by Country
List of companies from research coverage that are profiled in the study
  • AbbVie Inc. (United States)
  • GSK plc (United Kingdom)
  • Johnson & Johnson Services, Inc. (United States)
  • Biogen (United States)
  • Merck & Co., Inc. (United States)
  • Novartis AG (Switzerland)
  • Bristol-Myers Squibb (United States)
  • Lilly (United States)
  • Eisai Co., Ltd. (Japan)
  • F. Hoffmann-La Roche Ltd. (Switzerland)
Additional players considered in the study are as follows:
H. Lundbeck A/S (United Kingdom) , Acadia Pharmaceuticals Inc. (United States) , Supernus Pharmaceuticals, Inc. (United States) , Alkermes (Ireland) , Amgen Inc. (United States)
Select User Access Type

Key Highlights of Report


Mar 2024 227 Pages 77 Tables Base Year: 2023 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Neurodegenerative Drugs Quantitative research analysis
Global Neurodegenerative Drugs Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The standard version of the report profiles players such as AbbVie Inc. (United States), GSK plc (United Kingdom), Johnson & Johnson Services, Inc. (United States), Biogen (United States), Merck & Co., Inc. (United States), Novartis AG (Switzerland), Bristol-Myers Squibb (United States), Lilly (United States), Eisai Co., Ltd. (Japan) and F. Hoffmann-La Roche Ltd. (Switzerland) etc.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
"Increasing Adoption of Cholinesterase Inhibitors" is seen as one of major influencing trends for Neurodegenerative Drugs Market during projected period 2023-2030.
The Neurodegenerative Drugs market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get a complete company list in our research coverage.

Know More About Global Neurodegenerative Drugs Report?

Have a Query? Click Here

Other Related Reports

Online Dietary Supplement Comprehensive Study by Type (Vitamins, Minerals, Herbal Products, Amino acids, Botanicals, Sports Nutrition), Application (Pharmaceuticals, Hospitals, Households), Forms (Dr...
$ 3800
Interventional Oncology Comprehensive Study by Cancer Type (Lung Cancer, Liver Cancer, Kidney Cancer, Other), Procedure Type (Ablation (Thermal Tumor Ablation, Non-Thermal Tumor Ablation ), Radiation...
$ 3350
Anti Diarrheal Drugs Comprehensive Study by Type (Prescription Drugs, OTC Drugs), Application (Children, Adults), Distribution Channel (Hospital, Pharmaceutical Clinics, Online Store) Players and Reg...
$ 3500
Ayurvedic Health and Personal Care Products Comprehensive Study by Type (Skin Care, Hair Care, Oral Care, Digestive Care, Others), Distribution Channels (Supermarkets and Hypermarkets, Drug Stores, S...
$ 3800
Endocrine Testing System Comprehensive Study by Type (Estradiol (E2) Test, Follicle Stimulating Hormone (FSH) Test, Human Chorionic Gonadotropin (HCG) Hormone Test, Luteinizing Hormone (LH) Test, Deh...
$ 3750
Mumps Vaccine Comprehensive Study by Type (Mono Vaccines, Combination Vaccines, Others), Distribution Channel (Hospitals Pharmacies, Drug Stores, Retail Pharmacies, Others), End User (Hospital, Pedi...
$ 3800